Update on Management of Medullary Thyroid Cancer w/ Dr. Hu

We are grateful to have guest lecturer, Dr. Mimi Hu present "Update on Management of Medullary Thyroid Carcinoma."

0:00 Webinar

2:40 Dr. Hu presents

3:44 Recognize Poor Prognostic Features
Dr. Hu describes how active surveillance is essential for managing metastatic medullary thyroid cancer (MTC), especially with poor prognostic indicators like calcitonin doubling time and lower survival rates in advanced disease.

14:09 Review the Available Treatments
Focal therapy options for MTC include conservative radiotherapy and bone-modifying agents, with case studies showing the effectiveness of SIR-Spheres Y90 Radioembolization.

20:44 Oncogenic Pathways
Dr. Hu shares how overexpression of VEGF and mutations in RET and RAS genes play a critical role in the oncogenesis of thyroid cancer, with multiple kinase inhibitors being tested in clinical trials.

36:20 When to Consider Systemic Therapy
Systemic therapy choices depend on molecular testing and are reserved for advanced or symptomatic MTC; ongoing clinical trials explore new therapeutic options.

47:15 Future Directions
Research focuses on understanding resistance mechanisms and exploring treatments for RAS-mutated cancers, with ongoing studies evaluating next-generation RET inhibitors and combination therapies.

52:16 Discussion with Q&A

** Check out our other programs! **

The THANC Guide
https://thancguide.org/

TIRO: Thyroid Int'l Recommendations Online
https://tiro.expert/

** Follow us on Twitter! **
@thancfoundation - https://shorturl.at/puwS0

THANC on FB - https://shorturl.at/svNY4